Real-world prescribing patterns of topical agents and treatment outcomes in melasma: a retrospective analysis
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20261931Keywords:
Melasma, Kojic acid, Hydroquinone, Melasma area and severity indexAbstract
Background: The present study aims to address the existing evidence gap by assessing prescription patterns for melasma management. Additionally, therapeutic effectiveness is measured through the melasma area and severity index (MASI) score over a structured 3 months observational period.
Methods: The present study is a retrospective, observational, multicentre study that includes data from dermatology OPD across various centres in India. The primary outcome was the assessment of frequency and type of topical agent prescribed, determining prescribing patterns of topical agents. Secondary outcomes included evaluation of effectiveness and safety of topical agents with changes in MASI score from baseline to 3 months post-treatment. Data from all centres were collected as per the protocol and proforma and compiled to summarize prescribing pattern of topical agents and associated demographic data.
Results: The prescribing patterns showed that there was greater use of depigmenting agents. Most frequently used depigmenting agents were kojic acid (KA) (70.72%) and hydroquinone (HQ) (70%). Mean reduction in MASI score of 39.5% was identified from baseline to 3 months post-treatment. Adverse event frequency was relatively minimal. Most patients tolerated the treatment well. Few patients experienced adverse events such as skin irritation (0.46%), erythema (0.24%), peeling (0.18%), and hyperpigmentation (0.16%).
Conclusions: This retrospective study provides an understanding of the role of KA and HQ as common prescribing topical agents for the management of melasma, exhibiting a safe and tolerable profile in large sample size. Significant improvement in MASI scores in 3 months suggests therapeutic advantage in routine clinical practice for melasma treatment.
References
Sood R, Tiwari P. Melasma management: Unveiling recent breakthroughs through literature analysis. Health Sci Rev. 2025;14:100213. DOI: https://doi.org/10.1016/j.hsr.2025.100213
Newcomer VD. A Melanosis of the Face (“Chloasma”). Arch Dermatol. 1961;83(2):284. DOI: https://doi.org/10.1001/archderm.1961.01580080114013
Nouveau S, Agrawal D, Kohli M, Bernerd F, Misra N, Nayak C. Skin hyperpigmentation in Indian population: Insights and best practice. Indian J Dermatol. 2016;61(5):487. DOI: https://doi.org/10.4103/0019-5154.190103
Choudhary S, K SB, Ghosh S, Sen D, Iyer S. Hyperpigmentation Management Perspectives: A Nationwide Survey of Indian Dermatologists. JDR. 2026;7(1):1. DOI: https://doi.org/10.46889/JDR.2026.7113
González-Molina V, Martí-Pineda A, González N. Topical Treatments for Melasma and Their Mechanism of Action. J Clin Aesthet Dermatol. 2022;15(5):19-28.
Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: A review of clinical trials. J Am Academy Dermatol. 2006;55(6):1048-65. DOI: https://doi.org/10.1016/j.jaad.2006.02.009
Austin E, Nguyen JK, Jagdeo J. Topical Treatments for Melasma: A Systematic Review of Randomized Controlled Trials. J Drugs Dermatol. 2019;18(11):S1545961619P1156X.
Crocco EI, Veasey JV, Boin MF, Lellis RF, Alves RO. A novel cream formulation containing nicotinamide 4%, arbutin 3%, bisabolol 1%, and retinaldehyde 0.05% for treatment of epidermal melasma. Cutis. 2015;96(5):337-42.
Piętowska Z, Nowicka D, Szepietowski JC. Understanding Melasma-How Can Pharmacology and Cosmetology Procedures and Prevention Help to Achieve Optimal Treatment Results? A Narrative Review. IJERPH. 2022;19(19):12084. DOI: https://doi.org/10.3390/ijerph191912084
Pennitz A, Kinberger M, Avila Valle G, Passeron T, Nast A, Werner RN. Self-applied topical interventions for melasma: a systematic review and meta-analysis of data from randomized, investigator-blinded clinical trials. Brit J Dermatol. 2022;187(3):309-17. DOI: https://doi.org/10.1111/bjd.21244
Sheth VM, Pandya AG. Melasma: A comprehensive update. J Am Academy Dermatol. 2011;65(4):699-714. DOI: https://doi.org/10.1016/j.jaad.2011.06.001
Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, et al. Topical retinoic acid (tretinoin) for melasma in black patients. A vehicle-controlled clinical trial. Arch Dermatol. 1994;130(6):727-33. DOI: https://doi.org/10.1001/archderm.1994.01690060057005
Farshi S, Mansouri P, Kasraee B. Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study. J Dermatological Treat. 2018;29(2):182-9. DOI: https://doi.org/10.1080/09546634.2017.1351608
Kagha K, Fabi S, Goldman M. Melasma’s Impact on Quality of Life. JDD. 2020;19(2):184-7. DOI: https://doi.org/10.36849/JDD.2020.4663
Hizli P, Kiliç FA, İçöz Aytaç S. Melasma Revisited: National Survey Reveals How Dermatologists Diagnose and Treat This Complex Skin Condition. J Cosmetic Dermatol. 2025;24(1):e16630. DOI: https://doi.org/10.1111/jocd.16630
Achar A, Rathi S. Melasma: A clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011;56(4):380. DOI: https://doi.org/10.4103/0019-5154.84722
Sarkar R, Handog EB, Das A, Bansal A, Macarayo MaJ, Keshavmurthy V, et al. Topical and Systemic Therapies in Melasma: A Systematic Review. Indian Dermatol Online J. 2023;14(6):769-81. DOI: https://doi.org/10.4103/idoj.idoj_490_22
Tehranchinia Z, Saghi B, Rahimi H. Evaluation of Therapeutic Efficacy and Safety of Tranexamic Acid Local Infiltration in Combination with Topical 4% HQ Cream Compared to Topical 4% HQ Cream Alone in Patients with Melasma: A Split-Face Study. Dermatol Res Pract. 2018;2018:1-5. DOI: https://doi.org/10.1155/2018/8350317
Ferreira Cestari T, Hassun K, Sittart A, De Lourdes Viegas M. A comparison of triple combination cream and HQ 4% cream for the treatment of moderate to severe facial melasma. J Cosmetic Dermatol. 2007;6(1):36-9. DOI: https://doi.org/10.1111/j.1473-2165.2007.00288.x
Gong Z, Lai W, Zhao G, Wang X, Zheng M, Li L, et al. Efficacy and Safety of Fluocinolone Acetonide, HQ, and Tretinoin Cream in Chinese Patients with Melasma: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study. Clin Drug Investig. 2015;35(6):385-95. DOI: https://doi.org/10.1007/s40261-015-0292-8
Tse TW. HQ for skin lightening: Safety profile, duration of use and when should we stop? J Dermatological Treat. 2010;21(5):272-5. DOI: https://doi.org/10.3109/09546630903341945
Cassiano DP, Espósito ACC, Da Silva CN, Lima PB, Dias JAF, Hassun K, et al. Update on Melasma-Part II: Treatment. Dermatol Ther (Heidelb). 2022;12(9):1989-2012. DOI: https://doi.org/10.1007/s13555-022-00780-4
Grimes PE. Melasma: Etiologic and Therapeutic Considerations. Arch Dermatol. 1995;131(12):1453. DOI: https://doi.org/10.1001/archderm.1995.01690240119022
Gan C, Rodrigues M. An Update on New and Existing Treatments for the Management of Melasma. Am J Clin Dermatol. 2024;25(5):717-33. DOI: https://doi.org/10.1007/s40257-024-00863-2
Maeda K. Timeline of the Development of Skin-Lightening Active Ingredients in Japan. Molecules. 2022;27(15):4774. DOI: https://doi.org/10.3390/molecules27154774
Tanveer N, Khan HMS, Akhtar N. Whitening effect of kojic acid dipalmitate loaded nanosized ethosomal gel for the treatment of hyperpigmentation: In vitro and in vivo characterization. J Cosmetic Dermatol. 2022;21(12):6850-62. DOI: https://doi.org/10.1111/jocd.15408
Zachary CM, Wang JV, Saedi N. Kojic Acid for Melasma: Popular Ingredient in Skincare Products. Skinmed. 2020;18(5):271-3.
Chan R, Park KC, Lee MH, Lee ES, Chang SE, Leow YH, et al. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 001, HQ 4, tretinoin 005) compared with HQ 4 cream in Asian patients with moderate to severe melasma. Brit J Dermatol. 2008;159(3):697-703. DOI: https://doi.org/10.1111/j.1365-2133.2008.08717.x
Astaneh R, Farboud E, Nazemi MJ. 4% HQ versus 4% HQ, 0.05% dexamethasone and 0.05% tretinoin in the treatment of melasma: a comparative study. Int J Dermatology. 2005;44(7):599-601. DOI: https://doi.org/10.1111/j.1365-4632.2004.02246.x
Lima PB, Dias JAF, Cassiano DP, Esposito ACC, Miot LDB, Bagatin E, et al. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% HQ cream for facial melasma: an evaluator‐blinded, randomized controlled trial. Acad Dermatol Venereol. 2021;35(9):1881-7. DOI: https://doi.org/10.1111/jdv.17344
Lima PB, Dias JAF, Cassiano D, Esposito ACC, Bagatin E, Miot LDB, et al. A comparative study of topical 5% cysteamine versus 4% HQ in the treatment of facial melasma in women. Int J Dermatol. 2020;59(12):1531-6. DOI: https://doi.org/10.1111/ijd.15146
32. Castanedo‐Cazares JP, Hernandez‐Blanco D, Carlos‐Ortega B, Fuentes‐Ahumada C, Torres‐Álvarez B. Near‐visible light and UV photoprotection in the treatment of melasma: a double‐blind randomized trial. Photoderm Photoimm Photomed. 2014;30(1):35-42. DOI: https://doi.org/10.1111/phpp.12086
Downloads
Published
How to Cite
Issue
Section
